In this issue:
- Third-generation EGFR inhibitors targeting T790M mutations:
- Efficacy and Safety of Befotertinib
- Efficacy and Safety of Limertinib
- Duration of durvalumab therapy
- RATIONALE-303 trial: tislelizumab vs docetaxel
- Nivolumab re-treatment after response to prior immunotherapy
- Opioids in advanced lung malignancy
- Lung cancer stigma
- ICI therapy and interaction with antacids:
- PPIs and H2RAs analysis 1
- PPIs and H2RAs analysis 2
- Lung cancer screening risk criteria
- Risks of lung cancer screening promotion
Please login below to download this issue (PDF)